DK2350005T3 - N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B - Google Patents

N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B

Info

Publication number
DK2350005T3
DK2350005T3 DK09778301T DK09778301T DK2350005T3 DK 2350005 T3 DK2350005 T3 DK 2350005T3 DK 09778301 T DK09778301 T DK 09778301T DK 09778301 T DK09778301 T DK 09778301T DK 2350005 T3 DK2350005 T3 DK 2350005T3
Authority
DK
Denmark
Prior art keywords
polymorph
aminophenyl
benzamide
aminomethyl
pyridin
Prior art date
Application number
DK09778301T
Other languages
Danish (da)
English (en)
Inventor
Matthias Schneider
Michael Gottfried
Jens Geisler
Gabriele Winter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2350005(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of DK2350005T3 publication Critical patent/DK2350005T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK09778301T 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B DK2350005T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
EP08163274 2008-08-29
PCT/EP2009/006381 WO2010022988A1 (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Publications (1)

Publication Number Publication Date
DK2350005T3 true DK2350005T3 (da) 2012-03-19

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09778301T DK2350005T3 (da) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B

Country Status (35)

Country Link
US (2) US7973166B2 (enExample)
EP (1) EP2350005B1 (enExample)
JP (1) JP4921616B2 (enExample)
KR (1) KR101073760B1 (enExample)
CN (1) CN102137846B (enExample)
AR (1) AR073226A1 (enExample)
AT (1) ATE538094T1 (enExample)
AU (1) AU2009286982C1 (enExample)
BR (1) BRPI0918580B8 (enExample)
CA (1) CA2735294C (enExample)
CO (1) CO6351736A2 (enExample)
CR (2) CR20110107A (enExample)
CY (1) CY1112645T1 (enExample)
DK (1) DK2350005T3 (enExample)
DO (1) DOP2011000064A (enExample)
EA (1) EA016811B1 (enExample)
EC (1) ECSP11010849A (enExample)
ES (1) ES2378640T3 (enExample)
HN (1) HN2011000609A (enExample)
HR (1) HRP20120183T8 (enExample)
IL (1) IL211276A (enExample)
MA (1) MA32610B1 (enExample)
MX (1) MX2011002248A (enExample)
MY (1) MY149058A (enExample)
NZ (1) NZ591387A (enExample)
PE (2) PE20110677A1 (enExample)
PL (1) PL2350005T3 (enExample)
PT (1) PT2350005E (enExample)
RS (1) RS52164B (enExample)
SI (1) SI2350005T1 (enExample)
SM (1) SMT201200026B (enExample)
SV (1) SV2011003846A (enExample)
TW (1) TWI427062B (enExample)
WO (1) WO2010022988A1 (enExample)
ZA (1) ZA201102285B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52164B (sr) 2008-08-29 2012-08-31 Bayer Pharma Aktiengesellschaft N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3168210A1 (en) 2015-11-13 2017-05-17 Sandoz Ag Crystalline forms of entinostat
WO2017216761A1 (en) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Solid forms of entinostat
CN110944978A (zh) * 2017-07-28 2020-03-31 杭州领业医药科技有限公司 含恩替诺特的化合物,其化合物晶型及其制备方法和药物组合物
CA3218617A1 (en) 2021-05-10 2022-11-17 Thierry Bonnaud Novel forms of entinostat

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP4360660B2 (ja) * 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
RS52164B (sr) 2008-08-29 2012-08-31 Bayer Pharma Aktiengesellschaft N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b

Also Published As

Publication number Publication date
CY1112645T1 (el) 2016-02-10
EP2350005B1 (en) 2011-12-21
SV2011003846A (es) 2011-07-27
CN102137846B (zh) 2014-04-23
ZA201102285B (en) 2011-12-28
KR101073760B1 (ko) 2011-10-13
JP4921616B2 (ja) 2012-04-25
US20100056585A1 (en) 2010-03-04
PE20141062A1 (es) 2014-09-19
KR20110038187A (ko) 2011-04-13
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
MX2011002248A (es) 2011-03-29
HRP20120183T1 (hr) 2012-03-31
TWI427062B (zh) 2014-02-21
ECSP11010849A (es) 2011-03-31
HRP20120183T8 (en) 2012-11-30
CR20110107A (es) 2011-04-28
CA2735294A1 (en) 2010-03-04
EP2350005A1 (en) 2011-08-03
NZ591387A (en) 2012-03-30
RS52164B (sr) 2012-08-31
PT2350005E (pt) 2012-03-12
PL2350005T3 (pl) 2012-05-31
US7973166B2 (en) 2011-07-05
CA2735294C (en) 2013-10-15
SI2350005T1 (sl) 2012-03-30
JP2012500819A (ja) 2012-01-12
SMT201200026B (it) 2012-07-10
AU2009286982B2 (en) 2011-06-23
USRE45499E1 (en) 2015-04-28
HK1160107A1 (en) 2012-08-10
CO6351736A2 (es) 2011-12-20
AR073226A1 (es) 2010-10-20
ES2378640T3 (es) 2012-04-16
WO2010022988A1 (en) 2010-03-04
CR20160465A (es) 2016-12-06
AU2009286982A1 (en) 2010-03-04
MA32610B1 (fr) 2011-09-01
IL211276A (en) 2014-07-31
DOP2011000064A (es) 2011-03-31
BRPI0918580B1 (pt) 2020-11-24
IL211276A0 (en) 2011-04-28
HN2011000609A (es) 2014-09-29
BRPI0918580A8 (pt) 2017-07-11
CN102137846A (zh) 2011-07-27
AU2009286982C1 (en) 2012-04-26
EA016811B1 (ru) 2012-07-30
ATE538094T1 (de) 2012-01-15
EA201100354A1 (ru) 2011-10-31
TW201014820A (en) 2010-04-16
BRPI0918580B8 (pt) 2021-05-25
BRPI0918580A2 (pt) 2015-12-01

Similar Documents

Publication Publication Date Title
SMT201200026B (it) Polimorfo B di N-(2-amminofenil)-4-[N-(piridin-3-il)-metossicarbonilamminometil]-benzamide (MS-275)
LTC2178888I2 (lt) Proteazomos inhibitoriai
DE602007003881D1 (de) Intraperikardiale Elektrode
EP2298731A4 (en) AMIDE COMPOUND
SMT201600057B (it) 3,5-diammino-6-cloro-n-(n-(4-(4-(2-(esil(2,3,4,5,6-pentaidrossiesil)ammino)etossi)fenil)butil)- carbammimidoil)pirazina-2-carbossammide
BRPI0818348A2 (pt) Derivados de n-(pirazol-3-il)-benzamida como ativadores de glicocinase
IL210642A (en) Devices for modulating cellular activity using ultrasound
EP2114634A4 (en) TESTING HEAD MANIPULATOR
ATE482185T1 (de) Heteroaroylsubstituierte serin-amide
IL211785A (en) Co-crystals of tramadol and naproxen
EP2280741A4 (en) IRREVERSIBLE ELECTROPORATION FOR THE PRODUCTION OF TISSUE OBJECTS
DK2178840T3 (da) Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere
IL206460A0 (en) Novel n-(2-amino-phenyl)-amide derivatives
BRPI1010884A2 (pt) composto inibidores hdac de alcanoilamino benzamida anilina
DK2010496T3 (da) 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
BRPI0909159A2 (pt) inibidores baseados em hidroxamato de desacetilases b
EP2258970A4 (en) TURNING OVER CARRIER
AP2013006834A0 (en) Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
BRPI0807281A2 (pt) Reduzindo os efeitos colaterais de tramadol
FI20086201A0 (fi) Epälineaarisuusmetriikan laskeminen
ATE512132T1 (de) Hydrochloridsalz von 5-ä3-(3- hydroxyphenoxy)azetidin-1-ylü-5-methyl-2,2- diphenylhexanamid
AP2015008407A0 (en) N-(2-(cyclic amine)ethyl) benzamide derivatives asP2X7 inhibitors
DK2041088T3 (da) Glycintransporter-1 inhibitorer
BRPI0912399A2 (pt) n-(2-amino-fenil)-acrilamidas